Schizophrenia - Articles - Page 4

Rethinking Topiramate

August 1, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

Topiramate can cause psychosis, or treat psychosis; worsen cognition, or improve it; cause depression or… You get the point. A look at the paradoxical world of psychopharmacology.

Management of Psychogenic Polydipsia

July 11, 2022

Victoria Hendrick, MD and Zachary Davis

Psychogenic polydipsia (PP), also known as primary polydipsia and potomania, was first described in the 1930s. It is surprisingly common with a prevalence rate between 3 to 25% in institutionalized patients. In this podcast, we will discuss how to accurately diagnose and manage psychogenic polydipsia in patients.

RESEARCH UPDATE

Topiramate Improves Weight in Schizophrenia in South Asians

June 1, 2022

Brian Miller, MD, PhD, MPH.

Brian Miller, MD, PhD, MPH. Dr. Miller has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This study looked at adjunctive topiramate for weight in a patient population inherently more vulnerable to cardiometabolic disturbance.

Quetiapine Reconsidered

June 1, 2022

Paul Riordan, MD.

Paul Riordan, MD. Assistant Consulting Professor of Psychiatry, Duke University. Dr. Riordan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

It is the best of drugs; it is the worst of drugs. Quetiapine (Seroquel) has a few benefits that are unmatched by other medications, and here we explore where it fits in depression, bipolar, schizophrenia, as well as off-label uses like anxiety and sleep.

RESEARCH UPDATE

Anticholinergic-Associated Cognitive Impairment in Schizophrenia

April 5, 2022

Brian Miller, MD, PhD, MPH.

Brian Miller, MD, PhD, MPH. Dr. Miller has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Antipsychotics, benztropine, and antidepressants have anticholinergic properties that can impair cognition. A study takes a deep dive into the magnitude of the risk of dementia in schizophrenia.

Assessing and Treating Catatonia

March 23, 2022

Stephan Heckers, MD

Stephan Heckers, MD William P. and Henry B. Test Professor Chair, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center. Psychiatrist-in-Chief, Vanderbilt Psychiatric Hospital. Nashville, TN. Dr. Heckers has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Patients experiencing catatonia often improve quickly with benzodiazepines, but how can we help patients who fail to respond? Dr. Heckers summarizes the management of catatonia, including refractory cases, and tells us of other illnesses to consider in our differential diagnoses.

Clozapine for Conduct Disorder in Schizophrenia

March 23, 2022

Anne Li, MD.

Anne Li, MD. Dr. Li has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Clozapine appears more effective than other antipsychotic medications in reducing violent behavior among patients with schizophrenia and a history of conduct disorder.

Vitamin B6 Lowers Prolactin on Antipsychotics

March 4, 2022

Brian Miller, MD, PhD, MPH.

Brian Miller, MD, PhD, MPH. Dr. Miller has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Higher antipsychotic doses are more likely to elevate prolactin. Enter: Vitamin B6.

EXPERT Q&A

Raising the Bar in Schizophrenia Treatment

January 31, 2022

Brian Miller, MD, PhD, MPH

Brian Miller, MD, PhD, MPH Professor of Psychiatry at the Medical College of Georgia, Augusta, and President of the Georgia Psychiatric Physicians Association. Dr. Miller receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute.

Dr. Miller discusses new options for negative symptoms, how to improve the therapeutic alliance, and what to do when clozapine doesn’t work in schizophrenia.

Establishing a Dose-Response Relationship for Lurasidone in Acute Schizophrenia

November 5, 2021

Garrett Rossi, MD.

Garrett Rossi, MD. Dr. Rossi has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Study suggests we may be underdosing this antipsychotic in schizophrenia.